【摘 要】
：
Background and Aim: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.Most hepatocellular carcinomas develop in the background of the advanced liver fibrosis and cirrhosi
【机 构】
：
重庆医科大学附属第二医院 重庆医科大学附属第一医院
【出 处】
：
中华医学会第五次全国病毒性肝炎慢性化、重症化基础与临床研究进展学术会议
论文部分内容阅读
Background and Aim: Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide.Most hepatocellular carcinomas develop in the background of the advanced liver fibrosis and cirrhosis through a stepwise accumulation of various genetic alterations from cirrhotic nodule to HCC.
其他文献
目的:直接抗病毒药物(Direct Acting Antiviral,DAAs)的上市使治愈慢性HCV感染成为现实,HCV感染治疗史上的这一巨大进展鼓舞了临床医生和科研人员探索治愈CHB的策略和方法.
目的:评估并比较CHB患者肝组织炎症及纤维化级别预测抗病毒疗效的能力.方法:将ALT≥4倍正常上限(upper limit of normal,ULN)和(或)HBVDNA≤6.55log10拷贝/ml设定为具备预测抗HBV有效的能力指标,纳入365例资料完整的CHB患者,根据患者肝组织炎症及纤维化程度不同分为四组,Ⅰ组(炎症＜G2组,纤维化＜S2),Ⅱ组(炎症≥G2组,纤维化＜S2),Ⅲ组(炎症
Background: Acute-on-chronic liver failure (ACLF) is a common serious hepatitis B virus (HBV)-related disease and has a poor prognosis.Until recently, initial combination antiviral treatment in ACLF p
目的:探讨慢性乙型病毒性肝炎(CHB)患者肝纤维化进展与血清病毒学标志的演变关系.方法:选择468例CHB患者,以其不同的肝纤维化分级由轻及重(S0-1,S2,S3-4)分为三组,分别统计三组患者肝纤维化分级与HBeAg状态及HBVDNA载量的关系.
目的:探讨恩替卡韦治疗不同肌酐清除率(Ccr)的乙型肝炎相关性肾炎患者的疗效及安全性.方法:人选在我院门诊或住院的108例乙型肝炎相关性肾炎患者,根据内生肌酐清除率将患者分成A组(Ccr≥80mL/分钟)32例、B组(50≤Ccr＜80mL/分钟)31例、C组(30≤Ccr＜50mL/分钟)25例、D组(Ccr＜30mL/分钟)20例,4组均在常规治疗基础上分别加用ETV0.5mg·d-1、0.5
目的:探讨肝硬化失代偿期并发多部位侵袭性真菌病的易感因素、诊断思路、治疗原则、用药推荐及药物剂量调整方案.方法:报道医院近期成功救治的一例肝硬化失代偿期并发多部位侵袭性真菌病病例并讨论.结果:肝硬化失代偿期并发多部位侵袭性真菌感染的报道不多,成功的治疗经验更少.
Background/purpose: NK cells are important antiviral effectors of innate immunity because of their contribution to virus elimination in chronic hepatitis B virus (HBV) infection.
Background: Naturally occurring mutations in HBV reverse transcriptase (RT) region have not been well characterized.
Background: The efficacy of continuous entecavir (ETV) therapy in patients with detectable HBV DNA at 48 weeks is still controversial Aim: To compare the long term continuous efficacy of ETV in chroni
OBJECTIVE: To develop a sensitive and accurate assay system for the quantification of covalently closed circular HBV DNA (cccDNA) for future clinic monitoring of cccDNA fluctuation during antiviral th